慢性心力衰竭应用酒石酸美托洛尔联合卡托普利治疗的疗效及不良反应

To analyze the efficacy and adverse reactions of metoprolol tartrate combined with captopril in the treatment of chronic heart failure

目的:分析酒石酸美托洛尔联合卡托普利治疗慢性心力衰竭的临床疗效及不良反应。方法:2019年5月-2020年6月收治慢性心力衰竭患者92例,随机双盲法分为两组,各46例,两组患者均给予常规治疗;对照组给予卡托普利治疗;观察组给予酒石酸美托洛尔联合卡托普利治疗。比较两组治疗效果。结果:观察组治疗总有效率显著高于对照组,差异有统计学意义(P<0.05);观察组治疗后左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)和左心室收缩末期内径(LVESD)等指标水平均优于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:酒石酸美托洛尔联合卡托普利治疗慢性心力衰竭的疗效显著,且治疗安全性较高。

Objective:To analyze the efficacy and adverse reactions of metoprolol tartrate combined with captopril in the treatment of chronic heart failure.Methods:From May 2019 to June 2020,92 patients with chronic heart failure were selected and randomly divided into two groups with 46 cases in each group.Both groups were given conventional treatment.The control group was given captopril treatment.The observation group was given metoprolol tartrate combined with captopril treatment.We compared the treatment effect of the two groups.Results:The total effective rate of the observation group was significantly higher than that of the control group,the difference was statistically significant(P<0.05).In the observation group,after treatment,the levels of left ventricular ejection fraction(LVEF),left ventricular end diastolic diameter(LVEDd)and left ventricular end systolic diameter(LVESD)were better than those in the control group,the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The efficacy of metoprolol tartrate combined with captopril in the treatment of chronic heart failure is significant,and the treatment safety is high.